Front Row Advisors’s Elevance Health ELV Stock Holding History

Front Row Advisors’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-27	Closed	-$10K	–	943
2021 Q2	$10K	Sell	27 -34	-56%	-$13K	﹤0.01%	563
2021 Q1	$22K	Sell	61 -10	-14%	-$3.22K	0.01%	383
2020 Q4	$23K	Sell	71 -2	-3%	-$614	0.01%	360
2020 Q3	$23K	Buy	73 +33	+83%	+$8.88K	0.01%	354
2020 Q2	$11K	Hold	40	–	–	0.01%	444
2020 Q1	$11K	Buy	40 +9	+29%	+$2.45K	0.01%	446
2019 Q4	$9K	Sell	31 -1	-3%	-$275	0.01%	475
2019 Q3	$8K	Buy	32 +10	+45%	+$2.74K	0.01%	482
2019 Q2	$6K	Sell	22 -2	-8%	-$546	﹤0.01%	540
2019 Q1	$7K	Sell	24 -3	-11%	-$868	0.01%	502
2018 Q4	$7K	Hold	27	–	–	0.01%	468
2018 Q3	$7	Buy	27 +3	+13%	+$779	﹤0.01%	484
2018 Q2	$6	Hold	24	–	–	﹤0.01%	544
2018 Q1	$5K	Buy	24 +13	+118%	+$3.05K	﹤0.01%	559
2017 Q4	$2K	Buy	+11	New	+$2.34K	﹤0.01%	669

Other funds holding ELV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Front Row Advisors's ELV Position: Q3 2021 in Review

Front Row Advisors sold out of Elevance Health (ELV) in Q3 2021, closing a stake of 27 shares — an estimated $10K sold.

Front Row Advisors first reported a position in ELV in Q4 2017 and held it in 15 quarters. The position peaked at $23K in Q4 2020. 1,214 funds tracked by Wall St. Rank hold ELV as of Q3 2021.

Front Row Advisors reported no remaining Elevance Health position as of Q3 2021 after selling out during the quarter.
Front Row Advisors sold 27 Elevance Health shares in Q3 2021, an estimated $10K.
Front Row Advisors first reported a position in Elevance Health in Q4 2017 and held it in 15 quarters.
Front Row Advisors's Elevance Health position peaked at $23K in Q4 2020.
1,214 funds tracked by Wall St. Rank held Elevance Health as of Q3 2021.

Based on Front Row Advisors's 13F filing for Q3 2021, filed 3 Nov 2021.